PE20050481A1 - Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents

Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Info

Publication number
PE20050481A1
PE20050481A1 PE2004001008A PE2004001008A PE20050481A1 PE 20050481 A1 PE20050481 A1 PE 20050481A1 PE 2004001008 A PE2004001008 A PE 2004001008A PE 2004001008 A PE2004001008 A PE 2004001008A PE 20050481 A1 PE20050481 A1 PE 20050481A1
Authority
PE
Peru
Prior art keywords
pyridin
bistrifluoromethylbenzyl
triazol
chlorophenyl
crystalline forms
Prior art date
Application number
PE2004001008A
Other languages
English (en)
Spanish (es)
Inventor
Shella Lenyonga Tameze
Pamela Kaye Footman
Carsten Timpe
David Scott Coffey
Carsten Weber
Alfio Borghese
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20050481A1 publication Critical patent/PE20050481A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2004001008A 2003-10-24 2004-10-20 Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona PE20050481A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
PE20050481A1 true PE20050481A1 (es) 2005-09-20

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001008A PE20050481A1 (es) 2003-10-24 2004-10-20 Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Country Status (28)

Country Link
US (1) US7381826B2 (https=)
JP (1) JP4959336B2 (https=)
KR (1) KR100848407B1 (https=)
CN (1) CN1863791B (https=)
AR (1) AR046131A1 (https=)
AT (1) ATE462700T1 (https=)
AU (1) AU2004285855B8 (https=)
BR (1) BRPI0415010B8 (https=)
CA (1) CA2542140C (https=)
CL (2) CL2009001311A1 (https=)
CR (1) CR8353A (https=)
DE (1) DE602004026333D1 (https=)
DK (1) DK1675846T3 (https=)
EA (1) EA008881B1 (https=)
EC (1) ECSP066517A (https=)
ES (1) ES2340772T3 (https=)
HR (1) HRP20100207T1 (https=)
IL (1) IL174926A0 (https=)
MA (1) MA28329A1 (https=)
MY (1) MY157375A (https=)
NO (1) NO335090B1 (https=)
NZ (2) NZ545917A (https=)
PE (1) PE20050481A1 (https=)
PT (1) PT1675846E (https=)
TW (1) TW200524906A (https=)
UA (1) UA82901C2 (https=)
WO (1) WO2005042515A1 (https=)
ZA (1) ZA200603234B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721069A2 (pt) 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
AU2018331267B2 (en) 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
HUE070000T2 (hu) 2018-09-28 2025-04-28 Vanda Pharmaceuticals Inc Tradipitant alkalmazása utazási betegségben
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
AU1343901A (en) * 1999-10-29 2001-05-14 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
CN1863791A (zh) 2006-11-15
BRPI0415010A (pt) 2006-11-07
AU2004285855A1 (en) 2005-05-12
UA82901C2 (en) 2008-05-26
AU2004285855B2 (en) 2010-12-23
ECSP066517A (es) 2006-10-10
KR100848407B1 (ko) 2008-07-28
EA200600829A1 (ru) 2006-08-25
ATE462700T1 (de) 2010-04-15
US20070078166A1 (en) 2007-04-05
IL174926A0 (en) 2006-08-20
MA28329A1 (fr) 2006-12-01
PT1675846E (pt) 2010-04-20
ZA200603234B (en) 2007-07-25
BRPI0415010A8 (pt) 2018-05-08
NO335090B1 (no) 2014-09-08
MY157375A (en) 2016-06-15
AR046131A1 (es) 2005-11-23
WO2005042515A1 (en) 2005-05-12
CN1863791B (zh) 2011-12-07
CA2542140A1 (en) 2005-05-12
DE602004026333D1 (de) 2010-05-12
ES2340772T3 (es) 2010-06-09
BRPI0415010B8 (pt) 2021-05-25
JP2007509143A (ja) 2007-04-12
NO20062371L (no) 2006-05-24
EA008881B1 (ru) 2007-08-31
KR20060061388A (ko) 2006-06-07
JP4959336B2 (ja) 2012-06-20
NZ545917A (en) 2009-11-27
US7381826B2 (en) 2008-06-03
BRPI0415010B1 (pt) 2019-07-09
NZ580480A (en) 2010-02-26
CL2009001311A1 (es) 2009-10-02
CL2009001310A1 (es) 2009-12-04
HRP20100207T1 (hr) 2010-05-31
TW200524906A (en) 2005-08-01
DK1675846T3 (da) 2010-05-31
CA2542140C (en) 2012-05-29
AU2004285855B8 (en) 2011-04-28
CR8353A (es) 2006-06-06

Similar Documents

Publication Publication Date Title
PE20050481A1 (es) Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
EP1576131A4 (en) EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
BRPI0414592A (pt) antagonistas de receptores de trombina
CR8475A (es) Fenilalanina-amidas sustituidas por benzoilo
SI1897548T2 (sl) Regulacija celic T
CR8291A (es) Formas polimorficas 3-(4-amino-1-oxo-1,3 dihidro -isoindol-2-il)-piperidin-2, 6-diona
ITVR20020062A1 (it) Preparazione estemporanea di periossiacidi organici stabili nel tempo
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
DK1663989T3 (da) Krystallisk form af bis(E)-7-[4(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl)aminopyrimidin-5-yl(3R,5S))-3-5-dihydroxyhept-6-ensyrecalciumsalt
DE60334973D1 (de) Aerosol-formulierungen von diisobutyryl apomorphine
IS8307A (is) Fenýl eða pýridýl amíð efnasambönd sem prostaglandín E2 mótlyf
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
DK1476162T3 (da) Kontrolleret syntese af ziprasidone
IS8425A (is) Hámörkuð tjáning af HPV 58 L1 í gersveppi
MEP12708A (en) Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
DE602005016297D1 (de) Antithrombotische diamide
FR2857115B1 (fr) Compatibilite des revisions de modules interchangeables
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
EP1711477A4 (en) NEW CRYSTALLINE FORMS OF INHIBITOR OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE TYPE 1
EP1578393A4 (en) PRIMARY RAT HEPATOCYTIC TOXICITY MODELING
HRP20050607B1 (hr) Supstituirani benzizoksazol sulfonamid hiv proteazni inhibitori širokog spektra
AR053989A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas y procesos de obtencion.
PE20040160A1 (es) 1,2-dihidropirazol-3-onas que controlan citoquinas inflamatorias
ATE377639T1 (de) Neue klebemittel, die diacetale enthalten
ITMI20040433A1 (it) Composizioni di stucco sintetico

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed